Efficacy and Safety of the New Appetite Suppressant, Liraglutide: A Meta-Analysis of Randomized Controlled Trials

BACKGROUND: Obesity is a chronic disease associated with metabolic diseases such as diabetes and cardiovascular disease. Since the U.S. Food and Drug Administration approved liraglutide as an anti-obesity drug for nondiabetic patients in 2014, it has been widely used for weight control in overweight...

Descripción completa

Detalles Bibliográficos
Autores principales: Moon, Shinje, Lee, Jibeom, Chung, Hye Soo, Kim, Yoon Jung, Yu, Jae Myung, Yu, Sung Hoon, Oh, Chang-Myung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Endocrine Society 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8258332/
https://www.ncbi.nlm.nih.gov/pubmed/34139800
http://dx.doi.org/10.3803/EnM.2020.934

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8258332/
https://www.ncbi.nlm.nih.gov/pubmed/34139800
http://dx.doi.org/10.3803/EnM.2020.934

Ejemplares similares